Expect A 10% Annual Return On This Enbridge Preferred Stock
Discover why this Enbridge preferred stock outshines common stock with lower risk, higher yields, and an expected 10.5% ...
ETF Daily News17d
Global Retirement Partners LLC Trims Stake in Invesco Variable Rate Investment Grade ETF (NASDAQ:VRIG)
Finally, Trademark Financial Management LLC lifted its holdings in Invesco Variable Rate Investment Grade ETF by 3.8% during the 3rd quarter. Trademark Financial Management LLC now owns 21,745 ...
Phillies’ Cristopher Sanchez Ready To Take Yet Another Leap In 2025
Sanchez was NL Contact Manager of the Year in 2024. His team-friendly contract has club options on his first two free agent ...
The Manila Times9d
Fortuna Reports Results for the Fourth Quarter and Full Year 2024
Attributable net income for the period was $11.3 million compared to an attributable net loss of $92.3 million in Q4 2023.
Bonds are rising as stocks suffer February drop. But don't count on long-term bonds as a cushion.
Bonds are up so far in February, outperforming U.S. stocks as major equities benchmarks appeared on track for a monthly loss with just a few trading days to go until March.
12 Best NYSE Penny Stocks to Buy According to Analysts
President Trump’s tariffs on Canada and Mexico went live on March 4, 2025, after a one-month moratorium, prompting ...
Global Net Lease Reports Fourth Quarter and Full Year 2024 Results
Completed $835 Million in Dispositions in 2024, Surpassing High-End of Increased Guidance– Reduced Net Debt by $734 million in 2024; Improved ...
manilatimes8d
Gold Bull Announces Shareholder Approval, Receipt of Court Approval and Expected Closing Date of Borealis Arrangement
The property possesses high grade expansion potential with excellent historical ... environmental compliance and changes in ...
Business Wire3d
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...